NeuroSense Therapeutics Ltd. NRSN
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Net Income | 0.00% | -36.25% | 0.00% | -- | |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | -- | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | 0.00% | 484.31% | 0.00% | -- | |
| Change in Net Operating Assets | 0.00% | 140.25% | 0.00% | -- | |
| Cash from Operations | 0.00% | 8.23% | 0.00% | -- | |
| Capital Expenditure | 0.00% | 40.00% | 0.00% | -- | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | 0.00% | 200.00% | 0.00% | -- | |
| Cash from Investing | 0.00% | 138.46% | 0.00% | -- | |
| Total Debt Issued | -- | -- | -- | -- | |
| Total Debt Repaid | -- | -- | -- | -- | |
| Issuance of Common Stock | 0.00% | 133.31% | 0.00% | -- | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | 0.00% | 13.85% | 0.00% | -- | |
| Cash from Financing | 0.00% | 140.66% | 0.00% | -- | |
| Foreign Exchange rate Adjustments | 0.00% | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | 0.00% | 81.56% | 0.00% | -- | |